Together, these findings indicated that the upregulation of ACSL4 was associated with increased infiltration of CD8+ T cells and, subsequently, facilitated the expression of immune checkpoint-related genes, which improved response to immunotherapy in BLCA. The gene discussed is ACSL4; the disease is bladder transitional cell carcinoma.